Viridian Therapeutics: Multiple 2026 Catalysts and Pipeline Momentum Underpin Buy Rating

William Blair analyst Lachlan Hanbury Brown has reiterated their bullish stance on VRDN stock, giving a Buy rating on December 23.

Lachlan Hanbury Brown has given his Buy rating due to a combination of factors that position Viridian Therapeutics for a potentially pivotal 2026. He highlights that the company is approaching a key regulatory milestone with veligrotug for thyroid eye disease, which has been accepted for priority review by the FDA and could receive approval by mid-2026. In parallel, Viridian is already investing in launch readiness, including commercial infrastructure, market access planning, and medical affairs capabilities, which supports a credible path to near-term revenue generation.

Beyond this initial product opportunity, Hanbury Brown underscores the importance of upcoming Phase III data for elegrobart in both active and chronic thyroid eye disease, where he sees a strong likelihood of positive outcomes and meaningful uptake for a convenient self-administered subcutaneous formulation. He also points to pipeline expansion with an anti-TSHR antibody program targeting thyroid eye disease and Graves’ disease, as well as advancing the FcRn portfolio, with VRDN-008 data expected to serve as a potential value inflection point. Taken together with a solid balance sheet and multiple clinical and regulatory catalysts, these factors support his view that Viridian is well positioned for significant growth, justifying a Buy rating.

Hanbury Brown covers the Healthcare sector, focusing on stocks such as Apellis Pharmaceuticals, Viridian Therapeutics, and Ocular Therapeutix. According to TipRanks, Hanbury Brown has an average return of 30.4% and a 68.63% success rate on recommended stocks.